Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373: 1849 60. 564. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153 9. 565. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI- CLARITY study. JAMA. 2005;294:1224 32. 566. van der Heijden DJ, Westendorp IC, Riezebos RK, et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol. 2004; 44:20 4. 567. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi- dogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001 15. 568. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361: 1045 57. 569. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607 21. 570. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527 33. 571. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol. 2008;51:2220 7. 572. Steinhubl SR, Berger PB, Mann JTI, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411 20. 573. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:199S 233S. 574. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 575. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218 22. 576. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682 7. 577. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intra- coronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation. 2005;112:2946 50. 578. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97:98 105. 579. Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2010;106:1208 11. 580. Berger PB, Mahaffey KW, Meier SJ, et al. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J. 2002;143:841 6. 581. Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYo- cardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol. 2010;56:550 7. 582. Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29: 1495 503. 583. AstraZeneca. Brilinta REMS document. NDA 22-433. Reference ID: 2976456. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM264004. pdf. [Package insert]. Accessed September 9, 2011. 584. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial com- paring infarct artery stenting plus abciximab with stenting alone. Circu- lation. 2004;109:1704 6. 585. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angio-graphic reste- nosis rate after the placement of coronary stents following acute myo- cardial infarction. J Am Coll Cardiol. 2000;35:915 21. 586. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957 66. 587. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glyco-protein IIb/IIIa inhibition with coronary stenting for acute myocar-dial infarction. N Engl J Med. 2001;344:1895 903. 588. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarc- tion: a meta-analysis of randomized trials. JAMA. 2005;293:1759 65. 589. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percu- taneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933 40. 590. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705 13. 591. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Car- diovasc Interv. 2004;62:186 92. 592. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol. 2005;105:250 5. 593. Iversen A, Galatius S, Jensen JS. The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percuta- neous coronary intervention; intravenous versus intracoronary. Curr Cardiol Rev. 2008;4:293 9. 594. Wohrle J, Nusser T, Mayer C, et al. Intracoronary application of abciximab in patients with ST-elevation myocardial infarction. EuroIn- tervention. 2008;3:465 9. 595. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intra- coronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31 4. 596. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840 3. 597. Bertrand OF, Rodes-Cabau J, Larose E, et al. Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Am J Cardiol. 2010;105: 1520 7. 598. Deibele AJ, Kirtane AJ, Pinto DS, et al. Intracoronary bolus adminis- tration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Throm- bolysis. 2006;22:47 50. 599. Yang XC, Zhang DP, Wang LF, et al. [Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary inter- vention]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:517 22. 600. Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary eptifibatide (ICE) Trial. Circulation. 2010;121:784 91. 601. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol. 2010;22: 278 82. 602. Galache Osuna JG, Sanchez-Rubio J, Calvo I, et al. [Does intracoro-nary abciximab improve the outcome of percutaneous coronary inter- ventions? A randomized controlled trial]. Rev Esp Cardiol. 2006;59: 567 74. 603. Wu TG, Zhao Q, Huang WG, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J. 2008;72:1605 9. 604. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87:1020 5. 605. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362 6. 606. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007;49:1517 24. 607. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarc- tion: quantitative review of randomised trials. Lancet. 2006;367: 579 88. 608. Van t Hof AWJ, ten Berg JM, Heestermans T, et al. Prehospital ini- tiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multi-centre, double- blind, randomised controlled trial. Lancet. 2008;372:537 46. 609. ten Berg JM, van t Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446 55. 610. Ellis SG, Tendera M, de Belder MA, et al. 1-year survival in a ran- domized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. J Am Coll Cardiol Intv. 2009;2:909 16. 611. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358: 2205 17. 612. El Khoury C, Dubien PY, Mercier C, et al. Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study. Arch Cardiovasc Dis. 2010;103:285 92. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e635 613. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascu- larization. N Engl J Med. 1997;336:1689 96. 614. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syn- dromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999; 100:2045 8. 615. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623 9. 616. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary inter- vention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531 8. 617. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment- elevation acute coronary syndromes. Circulation. 2001;104:2767 71. 618. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angio- plasty. The EPIC Investigation. N Engl J Med. 1994;330:956 61. 619. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004;44:14 9. 620. EPISTENT Investigators. Randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87 92. 621. ESPIRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo- controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037 44. 622. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232 8. 623. Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627 35. 624. Hausleiter J, Kastrati A, Mehilli J, et al. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med. 2004;256:388 97. 625. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost. 2009;102: 428 36. 626. Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation. 2002;105:2347 54. 627. Danzi GB, Capuano C, Sesana M, et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutane- ous coronary intervention. Am J Cardiol. 2006;97:489 93. 628. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 1999;100:1977 82. 629. Gilchrist IC, O Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percuta- neous coronary intervention. Circulation. 2001;104:406 11. 630. Gurm HS, Tamhane U, Meier P, et al. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contem- porary randomized controlled trials. Circ Cardiovasc Interv. 2009;2: 230 6. 631. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angio- plasty: a meta-analysis. J Am Coll Cardiol. 2009;53:1668 73. 632. McKay RG, Boden WE. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syn- dromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Cardiol. 2001;16:364 9. 633. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of tirofiban for Outcomes and REstenosis. Circulation. 1997;96:1445 53. 634. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol. 2002;40: 662 8. 635. Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clin Ther. 2002;24:1332 44. 636. Stabile E, Nammas W, Salemme L, et al. The CIAO (Coronary Inter- ventions Antiplatelet-based Only) study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol. 2008; 52:1293 8. 637. Lincoff AM, Steinhubl SR, Manoukian SV, et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol Intv. 2008;1:639 48. 638. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfrac- tionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688 96. 639. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned gly- coprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853 63. 640. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696 703. 641. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORI- ZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149 59. 642. Schulz S, Mehilli J, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J. 2010;31:582 7. 643. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203 16. 644. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358: 2218 30. 645. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myo- cardial infarction) trial. J Am Coll Cardiol. 2009;54:1438 46. 646. Brieger D, Collet JP, Silvain J, et al. Heparin or enoxaparin anticoagu- lation for primary percutaneous coronary intervention. Catheter Car- diovasc Interv. 2011;77:182 90. 647. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943 50. 648. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary inter- vention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658 63. 649. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfrac- tionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45 54. 650. Montalescot G, Gallo R, White HD, et al. Enoxaparin versus unfrac- tionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in per- cutaneous coronary intervention patients, an international randomized evaluation) trial. J Am Coll Cardiol Intv. 2009;2:1083 91. 651. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354: 1464 76. 652. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295: 1519 30. 653. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between pro- cedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1061 5. 654. McGarry TF Jr, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123:1445 51. 655. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between acti- vated clotting time during angioplasty and abrupt closure. Circulation. 1996;93:667 71. 656. Brener SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994 8. 657. Tolleson TR, O Shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003;41: 386 93. 658. Doherty TM, Shavelle RM, French WJ. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2005;65:330 7. 659. Plante S, Cantor WJ, Goldman L, et al. Comparison of bivalirudin versus heparin on radial artery occlusion after transradial catheterization. Catheter Cardiovasc Interv. 2011;76:654 8. 660. Bertrand OF, Rodes-Cabau J, Rinfret S, et al. Impact of final activated clotting time after transradial coronary stenting with maximal antiplate- let therapy. Am J Cardiol. 2009;104:1235 40. 661. Cohen M, Levine GN, Pieper KS, et al. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv. 2010;75:928 35. 662. Collet JP, Montalescot G, Golmard JL, et al. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am Heart J. 2004;147:655 61. 663. Levine GN, Ferrando T. Degree of anticoagulation after one subcu- taneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis. 2004;17:167 71. 664. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163 70. 665. Drouet L, Bal dit Sollier C, Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J. 2009;158:177 84. 666. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163 70. 667. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular- weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med. 2007;167:2423 30. 668. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin- induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57: 177 84. 669. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocy- topenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15: 611 6. 670. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31:561 72. 671. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995;332:1374 6. 672. Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998;31:1449 59. 673. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfrac- tionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339 49. 674. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152: 887.e9 887.e14. 675. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine admin- istered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51:27 31. 676. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv. 2004;61:484 91. 677. Fischell TA, Haller S, Pulukurthy S, et al. Nicardipine and adenosine flush cocktail to prevent no-reflow during rotational atherectomy. Cardiovasc Revasc Med. 2008;9:224 8. 678. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following per- cutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol. 2001;37:1335 43. 679. Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:671 6. 680. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33:654 60. 681. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intra- coronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996; 39:113 8. 682. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intra- coronary adenosine as an adjunct to primary angioplasty in acute myo- cardial infarction. Circulation. 2000;101:2154 9. 683. Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004;148:611. 684. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no-reflow after percutaneous coronary intervention. Circulation. 1994; 89:2514 8. 685. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to rep- erfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775 80. 686. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aorto- coronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51: 394 9. 687. Stoel MG, Marques KM, de Cock CC, et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71: 283 9. 688. Werner GS, Lang K, Kuehnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocar-dial infarction. Catheter Cardiovasc Interv. 2002;57:444 51. 689. Weyrens FJ, Mooney J, Lesser J, et al. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol. 1995; 75:849 50. 690. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients data with long-term follow-up. Eur Heart J. 2007;28:443 9. 691. Fischell TA, Carter AJ, Foster MT, et al. Reversal of no reflow during vein graft stenting using high velocity boluses of intracoronary adeno- sine. Cathet Cardiovasc Diagn. 1998;45:360 5. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e637 692. Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv. 2002;57:305 9. 693. Iwasaki K, Samukawa M, Furukawa H. Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. Am J Cardiol. 2006;98:1354 6. 694. Matsuo H, Watanabe S, Watanabe T, et al. Prevention of no-reflow/ slow-flow phenomenon during rotational atherectomy: a prospective randomized study comparing intracoronary continuous infusion of ve- rapamil and nicorandil. Am Heart J. 2007;154:994 6. 695. Tsubokawa A, Ueda K, Sakamoto H, et al. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phe- nomenon during rotational atherectomy. Circ J. 2002;66:1119 23. 696. Fischell TA, Subraya RG, Ashraf K, et al. Pharmacologic distal protection using prophylactic, intragraft nicardipine to prevent noreflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol. 2007;19:58 62. 697. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator pre- vention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14: 299 302. 698. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, ran- domised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278 84. 699. Olivari Z, Rubartelli P, Piscione F, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 2003;41:1672 8. 700. Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001;38:409 14. 701. de Labriolle A, Bonello L, Roy P, et al. Comparison of safety, efficacy, and outcome of successful versus unsuccessful percutaneous coronary intervention in true chronic total occlusions. Am J Cardiol. 2008;102: 1175 81. 702. Rathore S, Matsuo H, Terashima M, et al. Procedural and inhospital outcomes after percutaneous coronary intervention for chronic total occlusions of coronary arteries 2002 to 2008: impact of novel guidewire techniques. J Am Coll Cardiol Intv. 2009;2:489 97. 703. Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation. 2005;112:2530 7. 704. Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J. 1993;126:561 4. 705. Deleted in proof. 706. He ZX, Mahmarian JJ, Verani MS. Myocardial perfusion in patients with total occlusion of a single coronary artery with and without col- lateral circulation. J Nucl Cardiol. 2001;8:452 7. 707. Aboul-Enein F, Kar S, Hayes SW, et al. Influence of angiographic collateral circulation on myocardial perfusion in patients with chronic total occlusion of a single coronary artery and no prior myocardial infarction. J Nucl Med. 2004;45:950 5. 708. Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. 2002;39:1096 103. 709. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary inter- vention in the current era compared with 1985 1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945 51. 710. Kirschbaum SW, Baks T, van den Ent M, et al. Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. Am J Cardiol. 2008;101:179 85. 711. Prasad A, Rihal CS, Lennon RJ, et al. Trends in outcomes after percu- taneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007;49:1611 8. 712. Safley DM, House JA, Marso SP, et al. Improvement in survival fol- lowing successful percutaneous coronary intervention of coronary chronic total occlusions: variability by target vessel. J Am Coll Cardiol Intv. 2008;1:295 302. 713. Sirnes PA, Golf S, Myreng Y, et al. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996;28: 1444 51. 714. Rubartelli P, Niccoli L, Verna E, et al. Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. J Am Coll Cardiol. 1998;32:90 6. 715. Mori M, Kurogane H, Hayashi T, et al. Comparison of results of intracoronary implantation of the Plamaz-Schatz stent with conventional balloon angioplasty in chronic total coronary arterial occlusion. Am J Cardiol. 1996;78:985 9. 716. Hoher M, Wohrle J, Grebe OC, et al. A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol. 1999;34:722 9. 717. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation. 1999;100:236 42. 718. Lotan C, Rozenman Y, Hendler A, et al. Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur Heart J. 2000; 21:1960 6. 719. Rahel BM, Suttorp MJ, Laarman GJ, et al. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Am Heart J. 2004; 147:e16 20. 720. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intrave- nous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002; 106:3063 7. 721. Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA to Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol. 1998;32:1619 23. 722. Al-Lamee R, Ielasi A, Latib A, et al. Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. Am J Cardiol. 2010;106: 1721 7. 723. de Feyter PJ, Serruys P, van den Brand M, et al. Percutaneous transluminal angioplasty of a totally occluded venous bypass graft: a challenge that should be resisted. Am J Cardiol. 1989;64:88 90. 724. de Feyter PJ, van Suylen RJ, de Jaegere PP, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol. 1993;21:1539 49. 725. Lee MS, Yang T, Kandzari DE, et al. Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft inter- vention. Am J Cardiol. 2010;105:1076 82. 726. Colombo A, Bramucci E, Sacca S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifur- cations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation. 2009;119:71 8. 727. Ferenc M, Gick M, Kienzle RP, et al. Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions. Eur Heart J. 2008;29:2859 67. 728. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation. 2010;121:1235 43. 729. Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation. 2006;114:1955 61. 730. Chen SL, Santoso T, Zhang JJ, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions results from the DKCRUSH-II (double kissing crush versus provisional stenting technique for treatment of coronary bifurcation lesions) Trial. J Am Coll Cardiol. 2011;57:914 20. 731. Moussa ID. Coronary artery bifurcation interventions: the disconnect between randomized clinical trials and patient centered decision- making. Catheter Cardiovasc Interv. 2011;77:537 45. 732. Aliabadi D, Tilli FV, Bowers TR, et al. Incidence and angiographic predictors of side branch occlusion following high-pressure intracoro-nary stenting. Am J Cardiol. 1997;80:994 7. 733. Galassi AR, Tomasello SD, Capodanno D, et al. Mini-crush versus T-provisional techniques in bifurcation lesions: clinical and angio- graphic long-term outcome after implantation of drug-eluting stents. J Am Coll Cardiol Intv. 2009;2:185 94. 734. Bhargava B, Waksman R, Lansky AJ, et al. Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. Catheter Cardiovasc Interv. 2001;54:295 300. 735. Chaudhry EC, Dauerman KP, Sarnoski CL, et al. Percutaneous coronary intervention for major bifurcation lesions using the simple approach: risk of myocardial infarction. J Thromb Thrombolysis. 2007;24:7 13. 736. Koo BK, Waseda K, Kang HJ, et al. Anatomic and functional evaluation of bifurcation lesions undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3:113 9. 737. Erglis A, Kumsars I, Niemela M, et al. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study. Circ Cardiovasc Interv. 2009;2:27 34. 738. Thuesen L, Kelbaek H, Klovgaard L, et al. Comparison of sirolimuse- luting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). Am Heart J. 2006;152:1140 5. 739. Chen S, Zhang J, Ye F, et al. Crush stenting with paclitaxel-eluting or sirolimus-eluting stents for the treatment of coronary bifurcation lesions. Angiology. 2008;59:475 83. 740. Latib A, Cosgrave J, Godino C, et al. Sirolimus-eluting and paclitaxel- eluting stents for the treatment of coronary bifurcations. Am Heart J. 2008;156:745 50. 741. Pan M, Suarez de LJ, Medina A, et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J. 2007;153:15 7. 742. Song YB, Hahn JY, Choi SH, et al. Sirolimus- versus paclitaxeleluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. J Am Coll Cardiol. 2010;55: 1743 50. 743. Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol. 2005;46:613 20. 744. Gil RJ, Gziut AI, Prati F, et al. Threshold parameters of left main coronary artery stem stenosis based on intracoronary ultrasound exam- ination. Kardiol Pol. 2005;63:223 31. 745. Sano K, Mintz GS, Carlier SG, et al. Assessing intermediate left main coronary lesions using intravascular ultrasound. Am Heart J. 2007;154: 983 8. 746. Park DW, Hong MK, Suh IW, et al. Results and predictors of angio- graphic restenosis and long-term adverse cardiac events after drug- eluting stent implantation for aorto-ostial coronary artery disease. Am J Cardiol. 2007;99:760 5. 747. Iakovou I, Ge L, Michev I, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol. 2004;44:967 71. 748. Kim SW, Mintz GS, Ohlmann P, et al. Comparative intravascular ultrasound analysis of ostial disease in the left main versus the right coronary artery. J Invasive Cardiol. 2007;19:377 80. 749. Courtis J, Rodes-Cabau J, Larose E, et al. Usefulness of coronary fractional flow reserve measurements in guiding clinical decisions in intermediate or equivocal left main coronary stenoses. Am J Cardiol. 2009;103:943 9. 750. Topol EJ, Ellis SG, Fishman J, et al. Multicenter study of percutaneous transluminal angioplasty for right coronary artery ostial stenosis. J Am Coll Cardiol. 1987;9:1214 8. 751. Jain SP, Liu MW, Dean LS, et al. Comparison of balloon angioplasty versus debulking devices versus stenting in right coronary ostial lesions. Am J Cardiol. 1997;79:1334 8. 752. Palmerini T, Sangiorgi D, Marzocchi A, et al. Ostial and midshaft lesions vs bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology. Eur Heart J. 2009;30:2087 94. 753. Williams M, Shaw LJ, Raggi P, et al. Prognostic value of number and site of calcified coronary lesions compared with the total score. J Am Coll Cardiol Img. 2008;1:61 9. 754. Fitzgerald PJ, Ports TA, Yock PG. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86:64 70. 755. Tanigawa J, Barlis P, Di Mario C. Heavily calcified coronary lesions preclude strut apposition despite high pressure balloon dilatation and rotational atherectomy: in-vivo demonstration with optical coherence tomography. Circ J. 2008;72:157 60. 756. Reimers B, von Birgelen C, van der Giessen WJ, et al. A word of caution on optimizing stent deployment in calcified lesions: acute coronary rupture with cardiac tamponade. Am Heart J. 1996;131:192 4. 757. Ellis SG, Popma JJ, Buchbinder M, et al. Relation of clinical presenta- tion, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation. 1994;89:882 92. 758. Warth DC, Leon MB, O Neill W, et al. Rotational atherectomy multi- center registry: acute results, complications and 6-month angio-graphic follow-up in 709 patients. J Am Coll Cardiol. 1994;24:641 8. 759. Khattab AA, Otto A, Hochadel M, et al. Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results. J Interv Cardiol. 2007;20:100 6. 760. Johnman C, Oldroyd KG, Mackay DF, et al. Percutaneous coronary intervention in the elderly: changes in case-mix and periprocedural outcomes in 31 758 patients treated between 2000 and 2007. Circ Car- diovasc Interv. 2010;3:341 5. 761. Singh M, Rihal CS, Gersh BJ, et al. Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary inter- vention: a single-institution experience. Circulation. 2007;115:2835 41. 762. Singh M, Peterson ED, Roe MT, et al. Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. Circ Cardiovasc Interv. 2009;2:20 6. 763. Moonen LA, van t Veer M, Pijls NH. Procedural and long-term outcome of primary percutaneous coronary intervention in octogenarians. Neth Heart J. 2010;18:129 34. 764. de Boer SP, Westerhout CM, Simes RJ, et al. Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient s age. J Am Coll Cardiol Intv. 2010;3:324 31. 765. Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol. 2008;51:2385 95. 766. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006;27:994 1005. 767. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288:3124 9. 768. Mueller C, Neumann FJ, Roskamm H, et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1450 consecutive patients. J Am Coll Cardiol. 2002;40:245 50. 769. Singh M, Rihal CS, Gersh BJ, et al. Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol. 2008;51:2313 20. 770. Jneid H, Fonarow GC, Cannon CP, et al. Sex differences in medical care and early death after acute myocardial infarction. Circulation. 2008;118: 2803 10. 771. Mehta RH, Bufalino VJ, Pan W, et al. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association s Get With the Guidelines program. Am Heart J. 2008;155:1059 67. 772. Solinas E, Nikolsky E, Lansky AJ, et al. Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007;50: 2111 6. 773. Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis. 2006;48:392 401. 774. Weiner DE, Krassilnikova M, Tighiouart H, et al. CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. BMC Nephrol. 2009;10:26. 775. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291: 2727 33. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e639 776. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009;2:222 9. 777. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 2002;105:2253 8. 778. Stolker JM, Kennedy KF, Lindsey JB, et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model rrom the EVENT Registry. Circ Cardiovasc Interv. 2010;3:327 34. 779. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31 41. 780. Gault MH, Longerich LL, Harnett JD, et al. Predicting glomerular function from adjusted serum creatinine. Nephron. 1992;62:249 56. 781. Levine GN, Berger PB, Cohen DJ, et al. Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals. Pharmacotherapy. 2006;26:1537 56. 782. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant. 2009;28: 1007 22. 783. Bader FM, Kfoury AG, Gilbert EM, et al. Percutaneous coronary inter- ventions with stents in cardiac transplant recipients. J Heart Lung Transplant. 2006;25:298 301. 784. Lee MS, Kobashigawa J, Tobis J. Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy. J Am Coll Cardiol Intv. 2008;1:710 5. 785. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005;111:1027 32. 786. Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv. 2008;1:10 9. 787. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54: 477 86. 788. Lim CC, Van Gaal WJ, Testa L, et al. With the universal definition, measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol. 2011;57:653 61. 789. Biancari F, D Andrea V, Di Marco C, et al. Meta-analysis of ran- domized trials on the efficacy of vascular closure devices after diagnos- tic angiography and angioplasty. Am Heart J. 2010;159:518 31. 790. Dauerman HL, Applegate RJ, Cohen DJ. Vascular closure devices: the second decade. J Am Coll Cardiol. 2007;50:1617 26. 791. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac cath- eterization: systematic review and meta-analysis. JAMA. 2004;291: 350 7. 792. Hoffer EK, Bloch RD. Percutaneous arterial closure devices. J Vasc Interv Radiol. 2003;14:865 85. 793. Vaitkus PT. A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention. J Invasive Cardiol. 2004;16:243 6. 794. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ ACG/AHA 2008 Expert Consensus Document on Reducing the Gastro- intestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122:2619 33. 795. Eisenberg MJ, Blankenship JC, Huynh T, et al. Evaluation of routine functional testing after percutaneous coronary intervention. Am J Cardiol. 2004;93:744 7. 796. Goel K, Lennon RJ, Tilbury RT, et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation. 2011;123:2344 52. 797. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-anal- ysis of randomized controlled trials. Am J Med. 2004;116:682 92. 798. Giannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarc- tion: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med. 2008;168:2194 204. 799. Witt BJ, Jacobsen SJ, Weston SA, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol. 2004;44: 988 96. 800. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694 740. 801. Thompson PD. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:1319 21. 802. Clark AM, Hartling L, Vandermeer B, et al. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659 72. 803. Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 per- formance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services. Circulation. 2007;116:1611 42. 804. Walther C, Mobius-Winkler S, Linke A, et al. Regular exercise training compared with percutaneous intervention leads to a reduction of inflam- matory markers and cardiovascular events in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2008;15:107 12. 805. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACC secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foun- dation. Circulation. 2011: published online before print November 3, 2011. 806. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circu- lation. 2002;106:3143 421. 807. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56: 320 8. 808. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 1670 81. 809. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437 45. 810. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 35. 810a.Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. 811. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardio- vascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438 45. 812. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227 39. 813. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. 814. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493 503. 815. Appel LJ, Frohlich ED, Hall JE, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation. 2011;123:1138 43. 816. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hyper- tension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3 10. 817. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117 24. 818. The ALLHAT Officers and Coordinators for the ALLHAT Collab- orative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [pub- lished corrections appear in JAMA. 2003;289:178; JAMA. 2004;291: 2916]. JAMA. 2002;288:2981 97. 819. SHEP Cooperative Research Group. Prevention of stroke by anti- hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255 64. 820. Duncan C, Stein MJ, Cummings SR. Staff involvement and special follow-up time increase physicians counseling about smoking ces- sation: a controlled trial. Am J Public Health. 1991;81:899 901. 821. Cornuz J, Humair JP, Seematter L, et al. Efficacy of resident training in smoking cessation: a randomized, controlled trial of a program based on application of behavioral theory and practice with standardized patients. Ann Intern Med. 2002;136:429 37. 822. Rosser W, McDowell I, Newell C. Documenting smoking status: trial of three strategies. Can Fam Physician. 1992;38:1623 8. 823. Cummings SR, Richard RJ, Duncan CL, et al. Training physicians about smoking cessation: a controlled trial in private practice. J Gen Intern Med. 1989;4:482 9. 824. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guidelines for coronary artery bypass graft surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011: published online before print November 7, 2011, doi:10.1161/CIR.0b013e31823c074e. Accessed November 7, 2011. 825. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894 909. 826. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57:1251 63. 827. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713 8. 828. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363: 1909 17. 829. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning : A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537 57. 830. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopi- dogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305: 1097 105. 831. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667 78. 832. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56:1357 65. 833. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmaco- activos). J Am Coll Cardiol. 2008;51:986 90. 834. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126 30. 835. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399 409. 836. Moses JW, Dangas G, Mehran R, et al. Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome. Am J Cardiol. 2008;102:24J 8J. 837. Erbel R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med. 1998;339:1672 8. 838. Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:616 23. 839. Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006;295:1264 73. 840. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recur- rences in patients with coronary in-stent restenosis: a randomized con- trolled trial. JAMA. 2005;293:165 71. 841. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug- eluting and bare metal stents: comprehensive meta-analysis of ran- domized trials and observational studies. Circulation. 2009;119: 3198 206. 842. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082 9. 843. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circu- lation. 2004;110:1226 30. 844. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260 4. 845. Mishkel GJ, Moore AL, Markwell S, et al. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol. 2007;49:181 4. 846. Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation. 2004;109:2727 31. 847. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872 8. 848. Whan Lee C, Kim S, Suh J, et al. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Catheter Cardiovasc Interv. 2008; 71:594 8. 849. Lemos PA, van Mieghem CA, Arampatzis CA, et al. Post- sirolimuseluting stent restenosis treated with repeat percutaneous inter- vention: late angiographic and clinical outcomes. Circulation. 2004;109: 2500 2. 850. Cosgrave J, Melzi G, Corbett S, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J. 2007;153:354 9. 851. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002;106:1883 92. 852. Eisenberg MJ, Wilson B, Lauzon C, et al. Routine functional testing after percutaneous coronary intervention: results of the aggressive diagnosis of restenosis in high-risk patients (ADORE II) trial. Acta Cardiol. 2007;62:143 50. 853. Babapulle MN, Diodati JG, Blankenship JC, et al. Utility of routine exercise treadmill testing early after percutaneous coronary intervention. BMC Cardiovasc Disord. 2007;7:12, doi:10.1186/1471-2261-7-12. 854. Garzon PP, Eisenberg MJ. Functional testing for the detection of reste- nosis after percutaneous transluminal coronary angioplasty: a meta-anal- ysis. Can J Cardiol. 2001;17:41 8. 855. Beller GA. Stress testing after coronary revascularization too much, too soon. J Am Coll Cardiol. 2010;56:1335 7. 856. Shah BR, Cowper PA, O Brien SM, et al. Patterns of cardiac stress testing after revascularization in community practice. J Am Coll Cardiol. 2010;56:1328 34. 857. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiogra- phy summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108:1146 62. 858. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging executive summary: a report of the American College of Cardiology/American Heart Asso- Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e641 ciation Task Force on Practice Guidelines (ACC/AHA/ASNC Com- mittee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003;108:1404 18. 859. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation. 2004;110:588 636. 860. Anderson JL, Adams CD, Antman EM, et al. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Asso- ciation Task Force on Practice Guidelines. Circulation. 2011;123: e426 579. 861. Lewin R. Return to work after MI, the roles of depression, health beliefs and rehabilitation. Int J Cardiol. 1999;72:49 51. 862. Grines CL, Marsalese DL, Brodie B, et al., PAMI-II Investigators. Safety and cost-effectiveness of early discharge after primary angio- plasty in low risk patients with acute myocardial infarction. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998;31: 967 72. 863. Haskell WL. Rehabilitation of the coronary patient. In: Wenger NK, Hellerstein HK, editors. Design and Implantation of Cardiac Condi- tioning Programs. New York, NY: Churchill Livingstone; 1978. 864. Fidan D, Unal B, Critchley J, et al. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000 2010. QJM. 2007;100:277 89. 865. Barber K, Stommel M, Kroll J, et al. Cardiac rehabilitation for community-based patients with myocardial infarction: factors predicting discharge recommendation and participation. J Clin Epidemiol. 2001; 54:1025 30. 866. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316 22. 867. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group. Circulation. 2006;113: 456 62. 868. Jacobs AK, Babb JD, Hirshfeld JW Jr, et al. Task force 3: training in diagnostic and interventional cardiac catheterization. J Am Coll Cardiol. 2008;51:355 61. 869. Dangas GD, Popma JJ. Recertification in interventional cardiology. J Am Coll Cardiol Intv. 2008;1:332 4. 870. Levinson W, King TE Jr, Goldman L, et al. Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med. 2010;362:948 52. 871. Yeung AC. American board of internal medicine maintenance of certi- fication requirements. J Am Coll Cardiol Intv. 2008;1:598 9. 872. Hannan EL, Wu C, Walford G, et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation. 2005; 112:1171 9. 873. Post PN, Kuijpers M, Ebels T, et al. The relation between volume and outcome of coronary interventions: a systematic review and meta-anal- ysis. Eur Heart J. 2010;31:1985 92. 874. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom- onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 